

Development of Efflux Pumps and Inhibitors (EPIs) in *A. baumannii*

Lidan Xing, Prince Amoah Barnie, Zhaoliang Su* and Huaxi Xu*

Department of Immunology, Institute of Laboratory Medicine, Jiangsu University, Zhenjiang, PR China

Abstract

Over the past three decades, *Acinetobacter baumannii* has emerged as an important nosocomial pathogen worldwide. Certain strains of *A. baumannii* are now resistant to many common antimicrobial agents, including fluoroquinolone, and multidrug resistance (MDR) is often responsible for the failure of antibiotic therapy. Researchers have paid close attention to the emergency of *MDR-AB*, and *PDR* (pandrug-resistance)-*AB*, even *XDR* (extreme-drug resistance)-*AB* isolated from clinical patients, mediated primarily through the production of β -lactamases, aminoglycoside-modifying enzymes (*AMEs*), mutation in gene for DNA gyrase subunit A (*gyrA*) and DNA topoisomerase (*parC*), as well as efflux pumps. In this article, we discussed the roles of various efflux pumps expressed in *Acinetobacter baumannii* and efflux pump inhibitors (EPIs), aimed at providing an overview of the mechanism to antibiotics in *Acinetobacter baumannii*.

Keywords: *Acinetobacter baumannii*; Efflux Pumps; *RND*; *adeABC*; Efflux Pump Inhibitors (EPIs)

Introduction

Acinetobacter baumannii is a Gram-negative, non-fermenting, oxidase-negative and non-motile coccobacillus, [1]. It can survive in water, soil, surface of skin and hospital environment. It cause a series of opportunistic infections such as epidemic pneumonia, skin and soft tissue infections, bacteraemia, urinary tract infections and septicemia app:addword:septicemia in immunocompromised patients, especially in the intensive care unit [2]. With the overuse of broad-spectrum antibiotics, *A. baumannii* has become the mayor pathogen in nosocomial infections [3]. To make matters worse, therapeutic outcomes in patients are severely affected due to the emergency of acquired multidrug resistance. These multidrug resistant strains of *A. baumannii* employ resistant mechanisms such as the use of chromosomally encoded cephalosporinase, degradation of enzymes, modification or protection of the drug target sites, decreased permeability of the membrane and the active efflux of antibiotics [3,4]. Resistant mechanisms in *A. baumannii* have aroused researchers' widespread attention in last decades.

Recent studies show that over-expression of efflux system is an efficient mechanism for drug resistance. Various chromosomally encoded efflux systems, both intrinsic and acquired, have been characterized as contributing to *MDR* in *A. baumannii*. The best characterized are the *AdeABC*, first identified in an *MDR* clinical isolate *BM4454* [5], and *adeDE* in *Acinetobacter* Genomic DNA group 3 [6]. This review is focused on efflux mediated resistance in *A. baumannii*, especially on the resistance-nodulation-cell division (*RND*) family and EPIs.

Efflux Superfamilies in *Acinetobacter baumannii*

Efflux system, composed of an inner membrane protein (IM, such as *RND* efflux) linked by a major fusion protein (MFP) to an outer membrane factor (OMF), are able to extrude a wide range of substrates often unrelated in structure [7], these substrates include aminoglycosides, quinolones, tetracycline, and minocycline. According to the homology of amino acid sequence, five superfamilies of efflux systems are closely related to drug resistance: *RND* family, the major facilitator superfamily (*MFS*), multidrug and toxic compound extrusion (*MATE*) families, the small multidrug resistance (*SMR*) and the ATP-binding cassette (*ABC*) transporters [8] (Table 1). Among the efflux systems, *RND* pumps are the most prevalent systems in gram-negative bacteria [9-11].

RND superfamilies

Efflux pumps of the *RND* superfamily play a significant role in producing multidrug resistance in gram-negative bacteria [12], such as *AcrB* in *Escherichia coli*, *MexB* in *Pseudomonas aeruginosa* [3], and *AdeABC*, *AdeDE*, *AdeIJK*, *AdeFGH* in *Acinetobacter baumannii* [6,7,13-16]. Some efflux pumps of the *RND* family have been shown to play an important role in the colonization and persistence of bacteria in the host thereby maintaining the bacterium cell in steady state as well as expelling toxic compounds from the bacterium cell [17].

AdeABC

AdeABC, the major and the first identified efflux pump in *RND*, it is a kind of ATP-dependent multidrug transporter. In this efflux pumps, antimicrobials can be expelled from cells by utilizing the proton motive force. [4]. The *adeABC* operon encodes *AdeA* (Membrane Fusion Proteins, MFP), *AdeB* (Inner Membrane Efflux Transporters, IM) and *AdeC* (Outer Membrane Proteins, OMP). These three genes are contiguous in the genome. Adjacent to them are two-component regulatory systems, *adeR* and *adeS*, which specify proteins homologous to sensors and regulators of two-component systems, respectively (Figure 1). *AdeB*, which consist of 12 transmembrane fragments, has



Figure 1: Structure of *adeABC* system.

*Corresponding authors: Xu Huaxi, Department of Immunology, Jiangsu University, Xuefu Road 301, Zhenjiang, China, Tel: +86-511-887910; Fax: 86-511-88791739; E-mail: xuhx@ujs.edu.cn

Su Zhaoliang, Department of Immunology, Jiangsu University, Xuefu Road 301, Zhenjiang, China, Tel: +86-511-887910; Fax: 86-511-88791739; E-mail: szl30@yeah.net

Received November 06, 2013; Accepted December 16, 2013; Published January 07, 2014

Citation: Xing L, Barnie PA, Su Z, Xu H (2014) Development of Efflux Pumps and Inhibitors (EPIs) in *A. baumannii*. Clin Microbial 3: 135. doi:10.4172/2327-5073.1000135

Copyright: © 2014 Xing L, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Efflux Pumps	Energy resource	Substrates	
RND	adeABC	Aminoglycosides, tetracyclines, erythromycins, fluoroquinolones, β -lactams, chloramphenicol, trimethoprim, cefotaxime, minocycline, some toxicant and dyes such as ethidium bromide	
	adeDE	Ceftazidime, amikacin, ciprofloxacin, chloramphenicol, erythromycin, ethidium bromide, meropenem, rifamycin, tetracycline	
	adeIJK	Similar to adeABC, include β -lactams, tetracyclines, chloramphenicol, erythromycins, fluoroquinolones, trimethoprim, and sodium dodecyl sulfate (SDS) but not ethidium bromide	
	adeFGH	Chloramphenicol, clindamycin, tigecycline, fluoroquinolones, trimethoprim, sulfamethoxazole and various dyes such as ethidium bromide, sarranine	
	adeXYZ	β -Lactams, ciprofloxacin, tetracycline, rifampin, chloramphenicol	
MFS	Tet	TetA-tetracycline only; TetB- tetracycline and minocycline; TetM- tetracyclines	
	cmlA	Chloramphenicol	
	CraA	Chloramphenicol	
	AmvA	Mainly dyes, disinfectants, detergents; and only antibiotic-erythromycin	
	SmvA	Erythromycin, methyl viologen, quaternary ammonium salt	
MATE	abeM	Proton motive force	Fluoroquinolones, aminoglycosides, chloramphenicol, acriflavine, daunorubicin, rhodamine6G, ethidium bromide and so on
SMR	abeS	Proton motive force	Dyes, detergents; chloramphenicol, fluoroquinolones, erythromycin, and novobiocin
ABC	ABCB1	ATP hydrolysis	Cancer cells

Table 1: Efflux pump and its substrates.

the capacity to recognize antibiotics and extrude them out of cell, play a significant role in the efflux pump. Thus the *adeB* has been proposed to be an epidemiological tool for detecting clinical *MDR* strains. It has been shown that *adeC* is not essential for the *MDR* strains conferred by the pump, because a mutant displays similar resistance to the substrates of *AdeABC* to that of the parental strain when *adeC* is inactivated [18], but *AdeC* can expel antibiotics out of cell, because it is located in the epicyte and has porin as well. *AdeA*, which stabilizes OMP, allows antibiotics to pass the inner and the outer membranes of the bacteria without accumulating within the periplasm [13].

AdeABC is very common in both resistant and susceptible *A. baumannii* strains. Alexander et al. [19], show the *adeA*, *adeB*, *adeR* and *adeS* are present in 80% of 116 strains of *Acinetobacter*, while *adeC* is present in 40% [19,20] also found that 34 carbapenem resistant *A. baumannii* expressed all the 5 genes, whereas other 2 strains are defective of *adeC* [20]. Expression of *adeABC* is tightly regulated by the two-component regulatory system, *adeR-adeS*. These *adeS* and *adeR* are sensor kinase and response regulator, respectively [10,18]. They are located upstream of *adeABC* and are transcribed in the opposite direction [8]. Mutations in *AdeRS* have been shown confer to overexpression of *AdeABC*, whereas inactivation of *adeR-adeS* is responsible for susceptibility in *A. baumannii* [18], it is known that *adeR-S* acts as a transcriptional activator in the pump. Mutation in *adeR* (Pro116Leu) and *adeS* (Thr153Met or Gly30Asp) will cause overexpression of *AdeABC* [18], and an insertion of an *ISAbal* upstream from the operon can also lead to overexpression of *AdeABC*, thereby enhancing efflux effect [14,21]. It has been reported that the *AdeABC*-overexpressing strains confer resistance to aminoglycosides, and decrease susceptibility to fluoroquinolones, cefotaxime, tetracycline, chloramphenicol, erythromycin, trimethoprim, minocycline [13] and tigecycline [14,22]. Recent data suggest that this system decreased netilmicin susceptibility of *A. baumannii* [19]. However, the role of *AdeABC* in carbapenem resistance strains raises many controversies. According to [23], overexpression of *AdeABC* leads to significantly high-level resistant to carbapenems, especially to imipenem, meropenem, and other class D carbapenemases [23]. However, in *OXA-23*-producing strains, overexpression of *AdeABC* is associated with resistant to meropenem but not to imipenem following inactivation of the pump [20]. Moreover, the overexpression of the *AdeABC* efflux pump is suggested to confer high-level resistance to carbapenems in conjunction with carbapenem-hydrolyzing oxacillinases in clinical isolates [24,25]. Thus, researchers agreed that overexpression of *AdeABC* contributes

to carbapenem resistance, but other efflux mechanisms may probably also be involved. In addition, NaCl, in physiological concentrations, can induce significant tolerance to aminoglycosides, carbapenems, quinolones, and colistin among isolated clinical strains of *MDR A. baumannii*, resulting in broad-spectrum tolerance to antibiotics [26]. Several reports further suggest that *AdeABC* exhibits a wide substrate range that includes biocides, dyes and disinfectants, and other chemical substrates in *A. baumannii* [5,13,18].

AdeDE

The *adeDE* efflux pump has been reported to confer resistance to ceftazidime, amikacin, ciprofloxacin, chloramphenicol, erythromycin, rifampin, meropenem, tetracycline in *Acinetobacter genomic DNA group 3(GDG3)*[6,27] and imipenem in *A. baumannii* [28]. It however differs from *AdeABC*, *AdeDE* increases the host resistance to ceftazidime and rifampicin while *AdeABC* protects the host from cefotaxime. Unlike what was found for *AdeABC* efflux systems, the structural gene for the outer membrane proteins (OMP) is not found in downstream of the *adeDE* gene cluster [6].

Chu proved that 70% out of 83 *GDG3* isolates were positive for *adeE*, while all the 59 *GDG2* (*A. baumannii*) isolates were negative, and found that *adeE* was not only expressed in *GDG3*, but also exist in *GDG13TU* and *GDG17* isolates [27]. Lin found that *adeE* was only detected in *adeSR-adeABC/adeIJK/int1-negative* isolates that were relatively susceptible to some antibiotics, and also proved that *adeE* did not coexist with *adeIJK* and *adeABC*. In addition, mRNA expression of *adeE* was not observed in strains that were positive for *adeE* [29]. Thus, different distribution of *RND* genes may likely be used as indicators for differentiating *Acinetobacter* species. But recent studies suggest that *adeE* coexists with *adeB* in a small proportion of *A. baumannii* isolates [28].

AdeIJK

AdeIJK is the second identified efflux pump in *RND* families. *AdeIJK* encode a three-component *RND* efflux system consisting of *AdeI*, *AdeJ* and *AdeK*, which is similar to MFPs, inner membrane efflux transporters: *RND* proteins and OMFs, as in the *adeABC* efflux [30]. As opposed to *AdeABC*, *AdeIJK* is intrinsic present in all strains of *A. baumannii*. It contributes to resistance to β -lactams, chloramphenicol, tetracycline, erythromycin, lincosamides, fluoroquinolones, fusidic acid, novobiocin, rifampin, trimethoprim, acridine, pyronine, safranin,

imipenem and sodium dodecyl sulfate (SDS) but not to ethidium bromide [28,30]. Several reports have shown that the levels of *adeIJK* overexpression are lower than those of *adeABC*, suggesting a threshold for toxicity for the host and that *adeIJK* is tightly regulated [8,16,31].

There are no ORFs coding for regulatory proteins in the vicinity of the *adeIJK* genes, therefore expression of *adeIJK* seems not to be specifically regulated but controlled at integrated level. Recent study showed that *AdeN*, a TetR-Type regulator, regulates the expression of *AdeIJK* in *A. baumannii* and also represses expression of the *adeIJK* (16). Moreover, some strains can express *adeIJK*, *adeABC* and *int1* simultaneously in *MDR-AB* [29].

AdeFGH

AdeFGH, encoded by the *adeFGH* operon, also confers multidrug resistance when overexpressed [15]. Expression of *adeFGH* is regulated by LysR-type transcriptional regulator (*LTTR*), named *adeL*, which locate upstream from the operon and transcribed in the opposite direction [8]. Mutation in *adeL* may lead to the overexpression of *adeFGH* [32]. It is responsible for high-level resistance to fluoroquinolones, tetracyclines, tigecycline, chloramphenicol, trimethoprim, sulfamethoxazole and various dyes such as EB, sarranine but has little effect when compared to β -lactams, erythromycin, rifampin and aminoglycosides [15,33].

AdeFGH is also very popular in *A. baumannii*. PA β N is found to inhibit the ability of the *AdeFGH* pump to efflux chloramphenicol, trimethoprim and clindamycin in the *A. baumannii* strains [34].

AdeXYZ

AdeXYZ, chromosomally encoded efflux systems, shares more than 97% identity with *AdeIJK* [30]. *AdeXYZ* is found in *Acinetobacter GDG3*, *Acinetobacter GDG13TU* and *Acinetobacter GDG 17* [27]. *AdeX*, *adeY*, *adeZ* are similar to MFP, RND, OMP in RND efflux system. The identity of the theoretical peptides to *AdeX*, *AdeY* and *AdeZ* are 80, 89 and 87, respectively [27]. In addition, *AdeXYZ* and *AdeDE* are predominantly in *GDG3* while *AdeABC* efflux system is specific for *GDG2* [27]. Until now, the function of *adeXYZ* in antimicrobial resistance is not well understood.

MFS

MFS belong to prevalent efflux system. *Tet*, *cmlA*, *CraA*, *AmvA* and *SmvA* are the most clinically relevant pumps in *MFS* superfamily in *A. baumannii*. *TetA* confers resistance to tetracycline alone while *TetB* is involved in tetracycline and minocycline resistance, but these two efflux pumps have no effect on tigecycline [35]. Researchers have found no strain carry *TetA* and *TetB* simultaneously in 79 tetracycline-resistant *A. baumannii* clones [35]. *TetA*, *TetB* and *TetM* were all resistant to tetracyclines [36]. Another *MFS* resistant gene *cmlA*, found in *MDR A. baumannii* strain *AYE*, which is resistant to β -lactams (except imipenem, piperacillin-tazobactam, ticarcillin-clavulanate), aminoglycosides, fluoroquinolones, chloramphenicol, tetracycline, and rifampin, extrude chloramphenicol [37]. *CraA* is also reported to display intrinsic resistance to chloramphenicol [38]. Together with other efflux genes, *CraA* is overexpressed in response to NaCl exposure [26]. *AmvA*, a member of the *MFS* efflux pumps, mediates dyes, disinfectants and detergents resistance in *A. baumannii* [8,39]. Moreover, *SmvA* confers resistance in *A. baumannii* with erythromycin, methyl viologen and quaternary ammonium compounds [3].

MATE

MATE families have two energy sources: the PMF (proton motive force) and the sodium ion gradient [40]. A member of the

MATE family, *AbeM*, a H⁺-coupled multidrug efflux pump extrudes fluoroquinolones, aminoglycosides, chloramphenicol, trimethoprim, erythrocine, ethidium bromide, and dyes [41]. *AbeM* protein, which consists of 448 amino acid residues, contains numerous hydrophobic amino acid residues and 12 hydrophobic regions. The substrates for the *AbeM* efflux pump are not widely known as compared to *adeABC* [41]. Some studies have shown that expression of *abeM* is not related to resistance to cephalosporins or aztreonam [42]. To date the contribution to antimicrobial resistance of this system in clinical isolates remains unknown.

SMR

abeS, a chromosomally encoded *SMR* efflux pump, exhibits efflux effect in relation to chloramphenicol, fluoroquinolones, erythromycin, novobiocin, dyes and detergents in *A. baumannii* [43]. *abeS*, a 330-bp gene, encodes a 109-amino-acid protein, and displays 100% identity to the product of ORF *ABAYE1181*. It exhibits 51.8% identity to *E. coli EmrE* found in the *A. baumannii AYE* genome [37]. Subsequently, *abeS* is confirmed to be an energy-dependent efflux pump, and its extruding energy source is proton (H⁺) [43].

ABC

ATP-binding cassette (*ABC*) transporters mediate multidrug resistance though ATP-dependent drug efflux pumps. It can energize the transport of variety of compounds across biological membranes via ATP hydrolysis and confer cellular resistance to a broad spectrum of drug substrates [44]. *ABCBI*, is a 170 kD transmembrane glycoprotein from the super family of ATP-binding cassette and one of the most widely studied transporters that enable cancer cells to develop drug resistance [45]. The major mechanism of efflux is dependent on energy generated for protein transport through the hydrolysis of ATP [46]. *ABCBI*, also known as P-glycoprotein (P-gp) or multidrug resistance protein 1 (*MDR1*), serves as an ATP-dependent efflux pump for a variety of chemicals, including many antimicrobial agents [45].

The Development of Efflux Pump Inhibitors (EPIs)

Resistant to antibiotics is increasingly becoming a worldwide severe problem in recent decades. Efflux system plays significant roles in antibiotic resistance in *A. baumannii* and many other Gram-negative bacteria. Subsequently, efflux pump inhibitors were developed to decrease the resistant effects employed by efflux system. PA β N and CCCP were the best studied synthetic inhibitors while reserpine and verapamil are the most used EPIs in clinical practice in recent years. EPIs can increase the intracellular concentration of antibiotics expelled by efflux pumps, and then maintain the initial sensitivity to antibiotics associated with overexpression of efflux pumps [47] and decrease the frequency of resistant mutant strains [48]. EPIs can hinder efflux channel, block-up energy resources of efflux pumps and make bacterium cells sensitive to the antibiotics.

PA β N

PA β N (phenylalanine-arginine β -naphthylamide, also called MC-207 110), is a well studied EPI and has been described as a broad-spectrum efflux pump inhibitor. PA β N has no effect on bacteria cells itself, unless used synergistically with β -lactam [49], fluoroquinolones and macrocyclic antibiotics. It is known to reverse resistance in *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Enterococcus* and Gram-negative bacteria through increasing the level of accumulation of efflux pump substrates within the cell [50,51]. Many studies suggest that PA β N reduce the minimal inhibitory concentrations (MICs) of several β -lactam antibiotics such as chloramphenicol, rifaximin, tigecycline,

clarithromycin against *E. coli*, *E. aerogenes*, or *P. aeruginosa* [49,52-56]. Again, Pa β N is able to enhance the permeability of cell membrane to increase antibiotic levels in the bacterium cells [51].

CCCP

CCCP (Carbonyl cyanide-m-chlorophenylhydrazone) is a strong uncoupler that disturbs electrochemistry gradient to inhibit *RND*, *MATE*, *MFS* and *SMR*, whose driving force come from proton motive [57]. Thereby increasing intracellular concentrations of antibiotics. CCCP has become a necessary tool for studying efflux systems MICs. It is known that with CCCP, MICs of fluoroquinolone, chloramphenicol, gentamicin, amikacin, ceftazidime, cefoperazone/sulbactam and imipenem in *A. baumannii* decreases relatively as compared to without CCCP [58-64].

Reserpine and verapamil

Reserpine and verapamil can block-up substrates' channel to play its role. Alkaloid reserpine is the first identified inhibitor of *NorA*, but it is documented to be toxic to the host cell if used to inhibit the activity of *NorA* [65]. Compared to CCCP, reserpine decreases the MICs of nalidixic acid, ciprofloxacin and norfloxacin, and the reserpine affects isolates which are not affected by Pa β N. This therefore suggests that the two inhibitors may possibly act on different efflux pumps [66].

Others

NMP(1-(1-naphthylmethyl)-piperazine), can partially reverse *MDR* in *A. baumannii* [58], it has stronger effect than Pa β N when higher concentration (100 mg/L) was used, but its effect is limited at a lower concentration (25 mg/L) [54]. In addition, NMP is capable of inhibiting the overexpression of *RND* pumps in *Escherichia* [54]. Omeprazole and lansoprazole are proton pump inhibitors, which can suppress the activity of H⁺/K⁺-ATP enzyme. Omeprazole is effective in *Helicobacter pylori* and *Staphylococcus aureus* [67], but its function in *A. baumannii* is not clearly been documented.

Interestingly, researchers have found a natural EPI extracted from a plant which is used in Chinese medicine, named 5'-methoxyhydnocarpin (5'-MHC), which inhibits the *NorA MDR* pump of a human pathogenic *Staphylococcus aureus* when combined with antibiotics [68].

Conclusion

The positive rate of multidrug resistance *A. baumannii* is dramatically increased in recent decades all over the world, and the mechanism of resistance is complicated. Together with antibiotics, EPIs provide a new horizon to reverse bacterial resistance, but the studies are in preliminary stages. Its usage is known to be restricted to *in vitro* because the effective inhibitory concentration is much higher than the concentration used in clinical application, so it could be toxic if applied to patients. Investigators are recommended to research into these mechanisms explored by *A. baumannii* in other to produce effective and safe EPIs for clinical use.

Competing Financial Interests

The authors have declared that no competing interests exist.

Acknowledgements

This work was supported by the National Natural Science Foundation of China (31270947, 81072453, 31170849), the Natural Science Foundation of Colleges and Universities in Jiangsu Province and Innovation Fund for candidate of doctor in Jiangsu Province (Grant No. 09KJB310001 and CXZZ11_0593, respectively).

References

1. Montefour K, Frieden J, Hurst S, Helmich C, Headley D, et al. (2008) *Acinetobacter baumannii*: an emerging multidrug-resistant pathogen in critical care. Crit Care Nurse 28: 15-25.
2. Richmond GE, Chua KL, Piddock LJ (2013) Efflux in *Acinetobacter baumannii* can be determined by measuring accumulation of H33342 (bis-benzamide). J Antimicrob Chemother 68: 1594-1600.
3. Li XZ, Nikaido H (2009) Efflux-mediated drug resistance in bacteria: an update. Drugs 69: 1555-1623.
4. Vila J, Martí S, Sánchez-Céspedes J (2007) Porins, efflux pumps and multidrug resistance in *Acinetobacter baumannii*. J Antimicrob Chemother 59: 1210-1215.
5. Magnet S, Courvalin P, Lambert T (2001) Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in *Acinetobacter baumannii* strain BM4454. Antimicrob Agents Chemother 45: 3375-3380.
6. Chau SL, Chu YW, Houang ET (2004) Novel resistance-nodulation-cell division efflux system AdeDE in *Acinetobacter* genomic DNA group 3. Antimicrob Agents Chemother 48: 4054-4055.
7. Nikaido H, Takatsuka Y (2009) Mechanisms of RND multidrug efflux pumps. Biochim Biophys Acta 1794: 769-781.
8. Coyne S, Courvalin P, Périchon B (2011) Efflux-mediated antibiotic resistance in *Acinetobacter* spp. Antimicrob Agents Chemother 55: 947-953.
9. Nikaido H (2011) Structure and mechanism of RND-type multidrug efflux pumps. Adv Enzymol Relat Areas Mol Biol 77: 1-60.
10. Yoon EJ, Courvalin P, Grillot-Courvalin C (2013) RND-type efflux pumps in multidrug-resistant clinical isolates of *Acinetobacter baumannii*: major role for AdeABC overexpression and AdeRS mutations. Antimicrob Agents Chemother 57: 2989-2995.
11. Alvarez-Ortega C, Olivares J, Martínez JL (2013) RND multidrug efflux pumps: what are they good for? Front Microbiol 4: 7.
12. Sun Y, Cai Y, Liu X, Bai N, Liang B, et al. (2013) The emergence of clinical resistance to tetracycline. Int J Antimicrob Agents 41: 110-116.
13. Wiczorek P, Sacha P, Hauschild T, Zórawski M, Krawczyk M, et al. (2008) Multidrug resistant *Acinetobacter baumannii*--the role of AdeABC (RND family) efflux pump in resistance to antibiotics. Folia Histochem Cytobiol 46: 257-267.
14. Ruzin A, Keeney D, Bradford PA (2007) AdeABC multidrug efflux pump is associated with decreased susceptibility to tigecycline in *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* complex. J Antimicrob Chemother 59: 1001-1004.
15. Coyne S, Rosenfeld N, Lambert T, Courvalin P, Périchon B (2010) Overexpression of resistance-nodulation-cell division pump AdeFGH confers multidrug resistance in *Acinetobacter baumannii*. Antimicrob Agents Chemother 54: 4389-4393.
16. Rosenfeld N, Bouchier C, Courvalin P, Périchon B (2012) Expression of the resistance-nodulation-cell division pump AdelJK in *Acinetobacter baumannii* is regulated by AdeN, a TetR-type regulator. Antimicrob Agents Chemother 56: 2504-2510.
17. Piddock LJ (2006) Multidrug-resistance efflux pumps - not just for resistance. Nat Rev Microbiol 4: 629-636.
18. Marchand I, Damier-Piolle L, Courvalin P, Lambert T (2004) Expression of the RND-type efflux pump AdeABC in *Acinetobacter baumannii* is regulated by the AdeRS two-component system. Antimicrob Agents Chemother 48: 3298-3304.
19. Nemeč A, Maixnerova M, van der Reijden TJ, van den Broek PJ, Dijkshoorn L (2007) Relationship between the AdeABC efflux system gene content, netilmicin susceptibility and multidrug resistance in a genotypically diverse collection of *Acinetobacter baumannii* strains. J Antimicrob Chemother 60: 483-489.
20. Wong EW, Yusof MY, Mansor MB, Anbazhagan D, Ong SY, et al. (2009) Disruption of *adeB* gene has a greater effect on resistance to meropenems than *adeA* gene in *Acinetobacter* spp. isolated from University Malaya Medical Centre. Singapore Med J 50: 822-826.
21. Lopes BS, Amyes SG (2013) Insertion sequence disruption of *adeR* and ciprofloxacin resistance caused by efflux pumps and *gyrA* and *parC* mutations in *Acinetobacter baumannii*. Int J Antimicrob Agents 41: 117-121.

22. Ruzin A, Immermann FW, Bradford PA (2010) RT-PCR and statistical analyses of *adeABC* expression in clinical isolates of *Acinetobacter calcoaceticus*-*Acinetobacter baumannii* complex. *Microb Drug Resist* 16: 87-89.
23. Héritier C, Poirel L, Fournier PE, Claverie JM, Raoult D, et al. (2005) Characterization of the naturally occurring oxacillinase of *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 49: 4174-4179.
24. Marqué S, Poirel L, Héritier C, Brisse S, Blasco MD, et al. (2005) Regional occurrence of plasmid-mediated carbapenem-hydrolyzing oxacillinase OXA-58 in *Acinetobacter* spp. in Europe. *J Clin Microbiol* 43: 4885-4888.
25. Lee Y, Yum JH, Kim CK, Yong D, Jeon EH, et al. (2010) Role of OXA-23 and AdeABC efflux pump for acquiring carbapenem resistance in an *Acinetobacter baumannii* strain carrying the blaOXA-66 gene. *Ann Clin Lab Sci* 40: 43-48.
26. Hood MI, Jacobs AC, Sayood K, Dunman PM, Skaar EP (2010) *Acinetobacter baumannii* increases tolerance to antibiotics in response to monovalent cations. *Antimicrob Agents Chemother* 54: 1029-1041.
27. Chu YW, Chau SL, Houang ET (2006) Presence of active efflux systems AdeABC, AdeDE and AdeXYZ in different *Acinetobacter* genomic DNA groups. *J Med Microbiol* 55: 477-478.
28. Hou PF, Chen XY, Yan GF, Wang YP, Ying CM (2012) Study of the correlation of imipenem resistance with efflux pumps AdeABC, AdeJK, AdeDE and AbeM in clinical isolates of *Acinetobacter baumannii*. *Chemotherapy* 58: 152-158.
29. Lin L, Ling BD, Li XZ (2009) Distribution of the multidrug efflux pump genes, *adeABC*, *adeDE* and *adeJK*, and class 1 integron genes in multiple-antimicrobial-resistant clinical isolates of *Acinetobacter baumannii*-*Acinetobacter calcoaceticus* complex. *Int J Antimicrob Agents* 33: 27-32.
30. Damier-Piolle L, Magnet S, Brémont S, Lambert T, Courvalin P (2008) AdeJK, a resistance-nodulation-cell division pump effluxing multiple antibiotics in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 52: 557-562.
31. Coyne S, Guigon G, Courvalin P, Périchon B (2010) Screening and quantification of the expression of antibiotic resistance genes in *Acinetobacter baumannii* with a microarray. *Antimicrob Agents Chemother* 54: 333-340.
32. Maddocks SE, Oyston PC (2008) Structure and function of the LysR-type transcriptional regulator (LTTR) family proteins. *Microbiology* 154: 3609-3623.
33. Roca I, Espinal P, Vila-Farrés X, Vila J (2012) The *Acinetobacter baumannii* OxyMoron: Commensal Hospital Dweller Turned Pan-Drug-Resistant Menace. *Front Microbiol* 3: 148.
34. Cortez-Cordova J, Kumar A (2011) Activity of the efflux pump inhibitor phenylalanine-arginine β -naphthylamide against the AdeFGH pump of *Acinetobacter baumannii*. *Int J Antimicrob Agents* 37: 420-424.
35. Marti S, Fernandez-Cuenca F, Pascual A, Ribera A, Rodriguez-Bano J, et al. (2006) Prevalence of the *tetA* and *tetB* genes as mechanisms of resistance to tetracycline and minocycline in *Acinetobacter baumannii* clinical isolates. *Enferm Infecc Microbiol Clin* 24: 77-80.
36. Huys G, Cnockaert M, Vaneechoutte M, Woodford N, Nemec A, et al. (2005) Distribution of tetracycline resistance genes in genotypically related and unrelated multiresistant *Acinetobacter baumannii* strains from different European hospitals. *Res Microbiol* 156: 348-355.
37. Fournier PE, Vallenet D, Barbe V, Audic S, Ogata H, et al. (2006) Comparative genomics of multidrug resistance in *Acinetobacter baumannii*. *PLoS Genet* 2: e7.
38. Roca I, Marti S, Espinal P, Martinez P, Gibert I, Vila J (2009) CraA, a major facilitator superfamily efflux pump associated with chloramphenicol resistance in *Acinetobacter baumannii*. *Antimicrobial agents and chemotherapy* 53: 4013-4014.
39. Rajamohan G, Srinivasan VB, Gebreyes WA (2010) Molecular and functional characterization of a novel efflux pump, AmvA, mediating antimicrobial and disinfectant resistance in *Acinetobacter baumannii*. *J Antimicrob Chemother* 65: 1919-1925.
40. Piddock LJ (2006) Clinically relevant chromosomally encoded multidrug resistance efflux pumps in bacteria. *Clin Microbiol Rev* 19: 382-402.
41. Su XZ, Chen J, Mizushima T, Kuroda T, Tsuchiya T (2005) AbeM, an H⁺-coupled *Acinetobacter baumannii* multidrug efflux pump belonging to the MATE family of transporters. *Antimicrob Agents Chemother* 49: 4362-4364.
42. Bratu S, Landman D, Martin DA, Georgescu C, Quale J (2008) Correlation of antimicrobial resistance with beta-lactamases, the OmpA-like porin, and efflux pumps in clinical isolates of *Acinetobacter baumannii* endemic to New York City. *Antimicrob Agents Chemother* 52: 2999-3005.
43. Srinivasan VB, Rajamohan G, Gebreyes WA (2009) Role of AbeS, a novel efflux pump of the SMR family of transporters, in resistance to antimicrobial agents in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 53: 5312-5316.
44. Song TT, Zhao J, Ying SH, Feng MG (2013) Differential contributions of five ABC transporters to multidrug resistance, antioxidation and virulence of *Beauveria bassiana*, an entomopathogenic fungus. *PLoS One* 8: e62179.
45. Ansbro MR, Shukla S, Ambudkar SV, Yuspa SH, Li L (2013) Screening Compounds with a Novel High-Throughput ABCB1-Mediated Efflux Assay Identifies Drugs with Known Therapeutic Targets at Risk for Multidrug Resistance Interference. *PLoS One* 8: e60334.
46. Borges-Walmsley MI, McKeegan KS, Walmsley AR (2003) Structure and function of efflux pumps that confer resistance to drugs. *Biochem J* 376: 313-338.
47. Zechini B, Versace I (2009) Inhibitors of multidrug resistant efflux systems in bacteria. *Recent Pat Antiinfect Drug Discov* 4: 37-50.
48. Martinez A, Lin J (2006) Effect of an efflux pump inhibitor on the function of the multidrug efflux pump CmeABC and antimicrobial resistance in *Campylobacter*. *Foodborne Pathog Dis* 3: 393-402.
49. Lamers RP, Cavallari JF, Burrows LL (2013) The Efflux Inhibitor Phenylalanine-Arginine Beta-Naphthylamide (PAbetaN) Permeabilizes the Outer Membrane of Gram-Negative Bacteria. *PLoS One* 8: e60666.
50. Barrett JF (2001) MC-207110 Daiichi Seiyaku/Microcide Pharmaceuticals. *Curr Opin Investig Drugs* 2: 212-215.
51. Lomovskaya O, Warren MS, Lee A, Galazzo J, Fronko R, et al. (2001) Identification and characterization of inhibitors of multidrug resistance efflux pumps in *Pseudomonas aeruginosa*: novel agents for combination therapy. *Antimicrob Agents Chemother* 45: 105-116.
52. Noumedem JA, Mihasan M, Lacmata ST, Stefan M, Kuate JR, et al. (2013) Antibacterial activities of the methanol extracts of ten Cameroonian vegetables against Gram-negative multidrug-resistant bacteria. *BMC Complement Altern Med* 13: 26.
53. Kothary V, Scherl EJ, Bosworth B, Jiang ZD, Dupont HL, et al. (2013) Rifaximin resistance in *Escherichia coli* associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in *rpoB*, and activity of Phe-Arg-beta-naphthylamide-inhibitable efflux pumps. *Antimicrob Agents Chemother* 57: 811-817.
54. Pannek S, Higgins PG, Steinke P, Jonas D, Akova M, et al. (2006) Multidrug efflux inhibition in *Acinetobacter baumannii*: comparison between 1-(1-naphthylmethyl)-piperazine and phenyl-arginine-beta-naphthylamide. *J Antimicrob Chemother* 57: 970-974.
55. Peleg AY, Potoski BA, Rea R, Adams J, Sethi J, et al. (2007) *Acinetobacter baumannii* bloodstream infection while receiving tigecycline: a cautionary report. *J Antimicrob Chemother* 59: 128-131.
56. Peleg AY, Adams J, Paterson DL (2007) Tigecycline Efflux as a Mechanism for Nonsusceptibility in *Acinetobacter baumannii*. *Antimicrob Agents Chemother* 51: 2065-2069.
57. Poole K (2002) Outer membranes and efflux: the path to multidrug resistance in Gram-negative bacteria. *Curr Pharm Biotechnol* 3: 77-98.
58. Kuo HY, Chang KC, Kuo JW, Yueh HW, Liou ML (2012) Imipenem: a potent inducer of multidrug resistance in *Acinetobacter baumannii*. *Int J Antimicrob Agents* 39: 33-38.
59. Ma Z, Cai SX, Tong WC, Ruan SC, Wang H (2011) [Role of the AdeABC efflux pump in carbapenems resistance of clinical isolates of *Acinetobacter baumannii*]. *Nan Fang Yi Ke Da Xue Xue Bao* 31: 1378-1381.
60. Aathithan S, French GL (2011) Prevalence and role of efflux pump activity in ciprofloxacin resistance in clinical isolates of *Klebsiella pneumoniae*. *Eur J Clin Microbiol Infect Dis* 30: 745-752.
61. Zhang JP, Zhu W, Tian SF, Chu YZ, Chen BY (2010) Molecular characteristics and resistant mechanisms of imipenem-resistant *Acinetobacter baumannii* isolates in Shenyang, China. *J Microbiol* 48: 689-694.
62. Usui M, Uchiyama M, Baba K, Nagai H, Yamamoto Y, et al. (2011) Contribution of enhanced efflux to reduced susceptibility of *Salmonella enterica* serovar

- Choleraesuis to fluoroquinolone and other antimicrobials. J Vet Med Sci 73: 279-282.
63. Zhang Z, Liu ZQ, Zheng PY, Tang FA, Yang PC (2010) Influence of efflux pump inhibitors on the multidrug resistance of *Helicobacter pylori*. World J Gastroenterol 16: 1279-1284.
64. Abdi-Ali A, Rahmani-Badi A, Falsafi T, Nikname V (2007) Study of antibiotic resistance by efflux in clinical isolates of *Pseudomonas aeruginosa*. Pak J Biol Sci 10: 924-927.
65. Markham PN, Westhaus E, Klyachko K, Johnson ME, Neyfakh AA (1999) Multiple novel inhibitors of the NorA multidrug transporter of *Staphylococcus aureus*. Antimicrob Agents Chemother 43: 2404-2408.
66. Ribera A, Ruiz J, Jimenez de Anta MT, Vila J (2002) Effect of an efflux pump inhibitor on the MIC of nalidixic acid for *Acinetobacter baumannii* and *Stenotrophomonas maltophilia* clinical isolates. J Antimicrob Chemother 49: 697-698.
67. Aeschlimann JR, Dresser LD, Kaatz GW, Rybak MJ (1999) Effects of NorA inhibitors on in vitro antibacterial activities and postantibiotic effects of levofloxacin, ciprofloxacin, and norfloxacin in genetically related strains of *Staphylococcus aureus*. Antimicrob Agents Chemother 43: 335-340.
68. Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K (2000) Synergy in a medicinal plant: antimicrobial action of berberine potentiated by 5'-methoxyhydrnocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci U S A 97: 1433-1437.